• Record revenue of $2.73 million for the June quarter, up 22.8% QoQ
• Revenue growth trajectory of 9.5% CQGR over the last 3 years
• US Remplir commercialisation program on track with first surgical use completed

Orthocell Ltd (ASX:OCC) has reported a record quarterly revenue of $2.73 million for the June 2025 quarter, up 22.8% from the previous record of $2.22 million in the March 2025 quarter. This result continues the company's quarterly revenue growth trajectory of a Compound Quarterly Growth Rate (CQGR) of 9.5% over the last 3 years. The material revenue uplift in the quarter was largely driven by stronger demand for Remplir, Orthocell's flagship nerve repair product, in Australia. Remplir is now used by over 200 surgeons across more than 165 hospitals in the country. Importantly, this record revenue result was achieved prior to any contribution from Remplir sales in the US, which are expected to ramp up during the first half of FY26. Orthocell recently announced the successful completion of its first surgery using Remplir in the US, a significant milestone in the company's US market rollout. The company has a network of 14 specialist nerve distributors with mature, direct-to-surgeon, hospital and other customer relationships across 25 US states, which is expected to support the anticipated ramp-up of sales in the US$1.6 billion nerve repair market. Orthocell has a strong balance sheet with approximately A$28.5 million cash at bank and no debt, positioning the company well to continue broadening its commercial footprint and growing revenues in existing and new markets.

Orthocell expects its US sales of the Remplir nerve repair product to gather pace in the coming months as more surgeons and healthcare professionals gain familiarity with the product. The company is well-positioned to accelerate growth in the US$1.6 billion nerve repair market over the coming months.